Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Punicic acid is a conjugated linolenic acid (CLnA) and an omega-5 polyunsaturated fatty acid primarily derived from pomegranate seed oil (*Punica granatum*). It is recognized for its diverse pharmacological properties, including potent antioxidant, anti-inflammatory, and anticancer activities. In oncology, punicic acid has demonstrated the ability to selectively impair ovarian cancer cell viability by inducing ferroptosis and mitochondrial dysfunction while sparing normal cells. It also acts as a potential sensitizer for cisplatin therapy. Beyond cancer, it is investigated for its role in managing metabolic disorders such as obesity and diabetes, improving lipid profiles, and providing cardiovascular protection. Mechanistically, it may interact with peroxisome proliferator-activated receptors (PPARs) and modulate lipid metabolism pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on punicic acid.